Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antineoplastic agent |
| gptkbp:activeIngredient |
gptkb:pemetrexed
|
| gptkbp:approvedBy |
gptkb:FDA
2004 |
| gptkbp:ATCCode |
L01BA04
|
| gptkbp:brand |
gptkb:Alimta
|
| gptkbp:CASNumber |
150399-23-8
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:hasMolecularFormula |
C20H19N5Na2O6
|
| https://www.w3.org/2000/01/rdf-schema#label |
pemetrexed disodium
|
| gptkbp:inhibitedBy |
dihydrofolate reductase
glycinamide ribonucleotide formyltransferase thymidylate synthase |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antifolate
|
| gptkbp:molecularWeight |
471.38 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
133332
151164 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
nausea fatigue rash neutropenia |
| gptkbp:UNII |
2Z4FSH2F2D
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
malignant pleural mesothelioma |
| gptkbp:bfsParent |
gptkb:pemetrexed
|
| gptkbp:bfsLayer |
7
|